Advanced Gastroesophageal Cancer
Publication Date: January 5, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
...reatmen...
...therapy and Targeted Therapy for Advanced Gastro...
...t-line Therapy...
...ommendation 1.1For HER2-negative patients...
...1.2For HER2-negative patients with esophageal or...
...ion 1.3For patients with ESCC and PD-L1 CPS ≥...
...1.4For patients with ESCC, and PD-L1 tumor...
...ndation 1.5For patients with HER2-positive...
...- or Third-line Ther...
...ion 2.1For patients with advanced gastroesophagea...
...2.2For HER2-positive patients wit...